BACKGROUND: The present study aimed to evaluate the clinical performance, in the daily practice of a busy catheterization laboratory, of a novel drug-eluting stent (DES) built with an ultra-thin-strut metallic platform, eluting sirolimus at low doses, abluminal coated with biodegradable polymers, and mounted in a low-compliant delivery system. METHODS: Prospective, single-arm study, comprising all consecutive patients undergoing percutaneous coronary intervention (PCI) with the Inspiron™ sirolimus-eluting stent (SES) (Scitech, Aparecida de Goiania, Brazil). The primary endpoint was the occurrence of major adverse cardiac events (MACE) [cardiac death, non-PCI related myocardial infarction (MI), or target vessel revascularization (TVR)]. RESULTS: A total of 470 patients were included, from which 51.3% were diabetics, 33.8% had triple-vessel disease, 15.3% had heart failure, 38.9% had at least one bifurcation treated, 19.8% were treated for a bare metal stent restenosis, and 61.9% had at least one type C lesion; one or more of these features were found in 96.0%. At 300 days, the rate target lesion revascularization was 5.4% and the rate of MACE was 8.1%. The incidence of definite or probable stent thrombosis was 0.4%, with no cases between 30 and 300 days. CONCLUSIONS: The novel stent is associated with excellent short and mid-term clinical outcomes in patients treated with PCI in the daily practice.
BACKGROUND: The present study aimed to evaluate the clinical performance, in the daily practice of a busy catheterization laboratory, of a novel drug-eluting stent (DES) built with an ultra-thin-strut metallic platform, eluting sirolimus at low doses, abluminal coated with biodegradable polymers, and mounted in a low-compliant delivery system. METHODS: Prospective, single-arm study, comprising all consecutive patients undergoing percutaneous coronary intervention (PCI) with the Inspiron™ sirolimus-eluting stent (SES) (Scitech, Aparecida de Goiania, Brazil). The primary endpoint was the occurrence of major adverse cardiac events (MACE) [cardiac death, non-PCI related myocardial infarction (MI), or target vessel revascularization (TVR)]. RESULTS: A total of 470 patients were included, from which 51.3% were diabetics, 33.8% had triple-vessel disease, 15.3% had heart failure, 38.9% had at least one bifurcation treated, 19.8% were treated for a bare metal stent restenosis, and 61.9% had at least one type C lesion; one or more of these features were found in 96.0%. At 300 days, the rate target lesion revascularization was 5.4% and the rate of MACE was 8.1%. The incidence of definite or probable stent thrombosis was 0.4%, with no cases between 30 and 300 days. CONCLUSIONS: The novel stent is associated with excellent short and mid-term clinical outcomes in patients treated with PCI in the daily practice.
Authors: Stephan Windecker; Patrick W Serruys; Simon Wandel; Pawel Buszman; Stanislaw Trznadel; Axel Linke; Karsten Lenk; Thomas Ischinger; Volker Klauss; Franz Eberli; Roberto Corti; William Wijns; Marie-Claude Morice; Carlo di Mario; Simon Davies; Robert-Jan van Geuns; Pedro Eerdmans; Gerrit-Anne van Es; Bernhard Meier; Peter Jüni Journal: Lancet Date: 2008-08-31 Impact factor: 79.321
Authors: Alessio Mattesini; Gioel G Secco; Gianni Dall'Ara; Matteo Ghione; Juan C Rama-Merchan; Alessandro Lupi; Nicola Viceconte; Alistair C Lindsay; Ranil De Silva; Nicolas Foin; Toru Naganuma; Serafina Valente; Antonio Colombo; Carlo Di Mario Journal: JACC Cardiovasc Interv Date: 2014-07 Impact factor: 11.195
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Hugo A Katus; Bertil Lindahl; David A Morrow; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis Journal: Circulation Date: 2012-08-24 Impact factor: 29.690
Authors: Giulio G Stefanini; Patrick W Serruys; Sigmund Silber; Ahmed A Khattab; Robert J van Geuns; Gert Richardt; Pawel E Buszman; Henning Kelbæk; Adrianus J van Boven; Sjoerd H Hofma; Axel Linke; Volker Klauss; William Wijns; Carlos Macaya; Philippe Garot; Carlo Di Mario; Ganesh Manoharan; Ran Kornowski; Thomas Ischinger; Antonio L Bartorelli; Pierre Gobbens; Stephan Windecker Journal: J Am Coll Cardiol Date: 2011-05-31 Impact factor: 24.094
Authors: Fernando Alfonso; Maria Jose Pérez-Vizcayno; Alberto Cárdenas; Bruno García Del Blanco; Bernhard Seidelberger; Andrés Iñiguez; Manuel Gómez-Recio; Mónica Masotti; M Teresa Velázquez; Juan Sanchís; Arturo García-Touchard; Javier Zueco; Armando Bethencourt; Rafael Melgares; Angel Cequier; Antonio Dominguez; Vicente Mainar; José R López-Mínguez; José Moreu; Vicens Martí; Raúl Moreno; Pilar Jiménez-Quevedo; Nieves Gonzalo; Cristina Fernández; Carlos Macaya Journal: J Am Coll Cardiol Date: 2014-01-08 Impact factor: 24.094
Authors: Scot Garg; Joanna Wykrzykowska; Patrick W Serruys; Ton de Vries; Pawel Buszman; Stanislaw Trznadel; Axel Linke; Karsten Lenk; Thomas Ischinger; Volker Klauss; Franz Eberli; Roberto Corti; William Wijns; Marie-Claude Morice; Carlo di Mario; Pawel Tyczynski; Robert Jan van Geuns; Pedro Eerdmans; Gerrit-Anne van Es; Bernhard Meier; Peter Jüni; Stephan Windecker Journal: EuroIntervention Date: 2011-03 Impact factor: 6.534
Authors: Pieter Cornelis Smits; Sjoerd Hofma; Mario Togni; Nicolás Vázquez; Mariano Valdés; Vassilis Voudris; Ton Slagboom; Jean-Jaques Goy; Andre Vuillomenet; Antoni Serra; Ramiro Trillo Nouche; Peter den Heijer; Martin van der Ent Journal: Lancet Date: 2013-01-30 Impact factor: 79.321
Authors: Pedro A Lemos; Marcelo Franken; Jose Mariani; Adriano Caixeta; Breno O Almeida; Fabio G Pitta; Guy F A Prado; Stefano Garzon; Felipe Ramalho; Gabriel Albuquerque; Ivanise M Gomes; Irisvaldo S de Oliveira; Leonardo Valle; Leonardo Galastri; Breno B Affonso; Felipe Nasser; Rodrigo G Garcia Journal: Cardiovasc Diagn Ther Date: 2022-02
Authors: Abhilash Akinapelli; Jack P Chen; Kristine Roy; Joseph Donnelly; Keith Dawkins; Barbara Huibregtse; Dongming Hou Journal: Curr Cardiol Rev Date: 2017